The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.185
Bid: 0.18
Ask: 0.19
Change: -0.02 (-9.76%)
Spread: 0.01 (5.556%)
Open: 0.205
High: 0.00
Low: 0.00
Prev. Close: 0.205
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

Tue, 09th Apr 2019 10:46

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo American, up 0.5%. The miner said its De Beers rough diamond sales in the third sales cycle of 2019 were about 10% higher than the year prior amid "stable" demand. Its third cycle sales in 2019 - as of Tuesday - stood at a provisional USD575 million. This was 9.7% higher than the USD524 million sales reported in the third cycle of 2018 and 16% up on the USD496 million sales reported for the second cycle of 2019.----------FTSE 100 - LOSERS----------Severn Trent, down 2.0%. JPMorgan downgraded the water company to Neutral from Overweight. ----------FTSE 250 - WINNERS----------NewRiver REIT, up 2.5%. The trust declared a fourth-quarter dividend of 5.4 pence per share, which is a 3% increase on the fourth quarterly dividend of 5.25 pence the prior year.----------FTSE 250 - LOSERS----------Pennon Group, down 2.0%. JPMorgan cut the utility stock to Neutral from Overweight. Hays, down 1.5%. Morgan Stanley downgraded the recruiter to Equal Weight from Overweight. Go-Ahead Group, 1.0%. HSBC lowered its rating on the transport operator to Hold from Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 60%. The pharmaceutical firm said it has signed a cannabinoid therapeutics agreement worth up to GBP51 million with private Canadian company Ebers Tech. The development, licensing and commercialisation agreement contains as much as GBP51 million of upfront, research and development, and milestone payments as well as long-term royalties of 20% of net sales, Nuformix said. Under the agreement, Ebers can use Nuformix's technology platforms to bring therapeutic cannabinoid products to market. Ebers is backed by financial sector leaders with connections to the US cannabinoid market. Nuformix is expecting "a significant upfront payment with further research and development and early-stage milestone payments of up to GBP1 million in 2019. More pre-clinical and milestone payments are likely in 2020 and 2021.Defenx, up 55%. The mobile security software firm said it has signed a software distribution and a software services agreement with majority shareholder BV Tech. The new distribution agreement modifies the terms of a previous deal from 2017. BV Tech - which has a 67% stake in Defenx - now has the sole right to sell Defenx's cyber security products to "bodies within the Italian defence, space, national security or critical infrastructures sector" until the end of 2023. For this, BV Tech will pay EUR1.0 million in three instalments before the end of the first half of 2019 and will also pay a 50% royalty fee to Defenx on any revenue from the sale of its products to clients exceeding EUR5.0 million. BV Tech has also committed, under the distribution agreement, to buy Defenx's products, with a minimal value of EUR1.2 million for a two-year period beginning in January 2019. Prior restrictions have been removed so that BV Tech can now distribute all of Defenx's products on an exclusive basis until the end of 2021. The software services agreement is entirely new. BV Tech will provide software services to Defenx, for which Defenx will pay a maximum of EUR1.2 million. One Media IP Group, up 12%. The digital media content company said annual profit rocketed due to strong streaming demand. The company posted a 63% increase in pretax profit to GBP486,504 for the year ended October 31, 2018, up from GBP297,601 the year before. One Media experienced 17% revenue growth to GBP2.7 million from GBP2.3 million. This was attributed to improved customer demand on streaming platforms, as well as revenue distributions from digital platforms. The company placed some of its music into film and television during its year, with its recording of Chopin's Nocturne Op No 2 in E-Flat Major appearing in Marvel's Daredevil and a new TV series by Jim Carey called 'Kidding'. As at October 31, One Media's cash balance stood at GBP5.6 million versus GBP335,664 the year before. The company added that is "well placed to benefit" from music industry growth and has "a strong pipeline of opportunities".----------OTHER MAIN MARKET AND AIM - LOSERS----------7digital Group, down 63%. The digital music and radio services company warned it requires further funding in the near future to continue trading. Having started a company review, 7digital is taking "a more circumspect" view of its sales pipeline, and it now believes it will need "material" equity or debt funding in the third quarter of 2019. "The board will assess financing options for the company however, it is likely that this would entail significant dilution for shareholders," the company said. As part of the group's new strategy it will no longer be giving a pre-close trading update for 2018, as it decides how to recognise the EUR4.0 million settlement received from MediaMarktSaturn in March. The case related to Media-Saturn subsidiary Juke Entertainment's music service, with Media-Saturn having wanted to end its relationship with 7digital. "The negotiations and ultimate loss of MediaMarktSaturn as a customer prior to John's arrival at the company has diverted management attention and led to disruption within the business during the first quarter as well as having a marked effect on customer sentiment," warned 7digital.Stride Gaming, down 13%. The online gaming operator said its revenue in the first half of its current financial year was lower than expected due to recently implemented regulatory changes. The company expects to report net gaming revenue for the six months to the end of February 5% lower than envisaged due to a disruption from fiscal and regulatory changes in the second half of calendar 2018. However, Stride does now see signs the impact has been largely absorbed and its business model is adjusting accordingly. Looking ahead, the company does not expect to recover the first half revenue shortfall through trading in the second half. Stride expects to report a strong performance from its Stride Together joint venture and is encouraged by further new partnership opportunities.----------

More News
12 Mar 2024 14:30

UK shareholder meetings calendar - next 7 days

Wednesday 13 March 
abrdn China Investment Co LtdGM re liquidation
Safestore Holdings PLCAGM
Wincanton PLCGM re takeover by CEVA Logistics
Thursday 14 March 
Angus Energy PLCGM
Bank of Georgia Group PLCGM re acquisition of Ameriabank CJSC
Blackrock Sustainable American Income Trust PLCAGM
Friday 15 March 
BlackRock Energy & Resources Income Trust PLCAGM
Chrysalis Investments LtdAGM
Quantum Exponential Group PLCGM re delisting from AQSE
TruSpine Technologies PLCAGM (adjourned 2022)
United Oil & Gas PLCGM re fundraise and share sub-division
Monday 18 March 
MGC Pharmaceuticals LtdGM re change of company name to Argent Biopharma
Schroder European Real Estate Investment Trust PLCAGM
Tuesday 19 March 
BlackRock Throgmorton Trust PLCAGM
Crest Nicholson Holdings PLCAGM
Eco Animal Health Group PLCGM re share buybacks
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Nuformix PLCAGM
Scirocco Energy PLCGM re requisitioned resolution to implement cash strategy
Various Eateries PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 Mar 2024 10:31

IN BRIEF: Nuformix announces subscription to raise GBP150,000

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
23 Oct 2023 12:38

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis.

Read more
18 Sep 2023 10:20

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year.

Read more
17 Aug 2023 15:43

UK shareholder meetings calendar - next 7 days

Friday 18 August 
Adams PLCAGM
ME Group International PLCGM re proposed share buyback
Oxford BioDynamics PLCGM re placing
Pathfinder Minerals PLCGM re disposal of the subsidiary
Monday 21 August 
Calculus VCT PLCAGM
Home REIT PLCGM re changes to the investment policy
Tuesday 22 August 
Cake Box Holdings PLCAGM
ReNeuron Group PLCAGM
RUA Life Sciences PLCAGM
Smoove PLCAGM
STM Group PLCAGM
Wednesday 23 August 
Brandshield Systems PLCAGM
James Latham PLCAGM
LifeSafe Holdings PLCGM re shareholder circular
Momentum Multi-Asset Value Trust PLCGM re appointment of the liquidators
Sovereign Metals LtdGM re share placement options
Thor Energy PLCGM re proposed share consolidation
Thursday 24 August 
Ananda Developments PLCAGM
Concurrent Technologies PLCAGM
CyanConnode Holdings PLCAGM
Nuformix PLCAGM
Oryx International Growth Fund LtdAGM
ThomasLloyd Energy Impact Trust PLCAGM
ThomasLloyd Energy Impact Trust PLCGM re market purchases of its own ordinary shares
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 May 2023 12:45

Nuformix loss narrows; near-term goal to focus on NXP002 asset

(Alliance News) - Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Apr 2023 12:14

Nuformix raises GBP70,000 to fund NXP002 programme

(Alliance News) - Nuformix PLC on Monday said it has raised GBP70,000 through a subscription for 35.0 million new shares at a price of 0.20 pence each.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Feb 2023 12:12

Nuformix progresses NXP002 trial after acquiring human tissue

(Alliance News) - Nuformix PLC on Wednesday said that, despite having to wait longer than expected, human disease tissue has now been acquired for its NXP002 programme.

Read more
13 Dec 2022 14:54

Nuformix interim loss virtually flat as continues work on drugs

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs.

Read more
23 Sep 2022 21:02

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
18 Aug 2022 16:01

UK shareholder meetings calendar - next 7 days

Friday 19 August 
Braemar Shipping Services PLCAGM
Citius Resources PLCAGM
Next Fifteen Communications Group PLCGM re acquisition of M&C Saatchi
Volex PLCAGM
Monday 22 August 
African Pioneer PLCAGM
Argentex Group PLCAGM
Nostrum Oil & Gas PLCGM operational update
Ondo InsurTech PLCAGM
Sabien Technology Group PLCGM re broker option
Scottish Investment Trust PLCGM re recombination of assets with JPMorgan Global Growth & Income plc
Trackwise Designs PLCAGM
Tuesday 23 August 
Bezant Resources PLCAGM
Livermore Investments Group LtdAGM
Xtract Resources PLCAGM
Wednesday 24 August 
Amur Minerals CorpGM subsidiary sale
Creightons PLCAGM
Goldstone Resources LtdAGM
Thursday 25 August 
Ince Group PLCGM fundraising
McBride PLCGM increase in borrowing limit
NatWest Group PLCGM re approval of special dividend
Nuformix PLCAGM
Triple Point Energy Efficiency Infrastructure Co PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Aug 2022 11:14

IN BRIEF: Nuformix shares rise on tolerability studies completion

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.